Chenchen Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chenchen Meng has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Wei Mao
Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 shared publications - Xinbin Zhou
Department of Cardiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
3 shared publications Chenxia Wu
The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications- Tiantian Zheng
The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China
2 shared publications - Tingting Chen
Zhejiang Key Laboratory of Integrative Chinese and Western Medicine for Diagnosis and Treatment of Circulatory Diseases, Zhejiang Hospital (Affiliated Zhejiang Hospital), Hangzhou, Zhejiang, China
2 shared publications - Zhengtian Lv
The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in Pharmacological Research
- Vol. 231, 108342
Beyond Lipid Lowering: Targeting lncRNAs as a Novel Therapeutic Strategy for Vascular Wall Defense in Atherosclerosis
- 13 July 2026
- Published by Elsevier in Pharmacological Research
- Vol. 231, 108342
Open AccessBeyond Lipid Lowering: Targeting lncRNAs as a Novel Therapeutic Strategy for Vascular Wall Defense in Atherosclerosis
- Open Access
- 5 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157122
The Tanyu Tongzhi Formula enhances IL-10 expression and macrophage efferocytosis to alleviate atherosclerosis in mice
- 5 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157122
Open AccessThe Tanyu Tongzhi Formula enhances IL-10 expression and macrophage efferocytosis to alleviate atherosclerosis in mice
- Open Access
- 20 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26740
The Critical Role of Faecalibacterium prausnitzii in Cardiovascular Diseases
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.
- 20 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26740
Open AccessThe Critical Role of Faecalibacterium prausnitzii in Cardiovascular Diseases
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.
- Open Access
- 8 January 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 407, 111379
A novel approach to the prevention and management of chemotherapy-induced cardiotoxicity: PANoptosis
- 8 January 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 407, 111379
Open AccessA novel approach to the prevention and management of chemotherapy-induced cardiotoxicity: PANoptosis
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3820591
Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy
The continuous development of antineoplastic therapy has significantly reduced the mortality of patients with malignant tumors, but its induced cardiotoxicity has become the primary cause of long‐term death in patients with malignant tumors. However, the pathogenesis of cardiotoxicity of antineoplastic therapy is currently unknown, and practical means of prevention and treatment are lacking in clinical practice. Therefore, how to effectively prevent and treat cardiotoxicity while treating tumors is a major challenge. Animal models are important tools for studying cardiotoxicity in antitumor therapy and are of great importance in elucidating pathophysiological mechanisms and developing and evaluating modality drugs. In this paper, we summarize the existing animal models in antitumor therapeutic cardiotoxicity studies and evaluate the models by observing the macroscopic signs, echocardiography, and pathological morphology of the animals, aiming to provide a reference for subsequent experimental development and clinical application.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3820591
Open AccessPreparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy
The continuous development of antineoplastic therapy has significantly reduced the mortality of patients with malignant tumors, but its induced cardiotoxicity has become the primary cause of long‐term death in patients with malignant tumors. However, the pathogenesis of cardiotoxicity of antineoplastic therapy is currently unknown, and practical means of prevention and treatment are lacking in clinical practice. Therefore, how to effectively prevent and treat cardiotoxicity while treating tumors is a major challenge. Animal models are important tools for studying cardiotoxicity in antitumor therapy and are of great importance in elucidating pathophysiological mechanisms and developing and evaluating modality drugs. In this paper, we summarize the existing animal models in antitumor therapeutic cardiotoxicity studies and evaluate the models by observing the macroscopic signs, echocardiography, and pathological morphology of the animals, aiming to provide a reference for subsequent experimental development and clinical application.